Brokerages forecast that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will report $131.22 million in sales for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for AMAG Pharmaceuticals’ earnings. The lowest sales estimate is $118.74 million and the highest is $153.24 million. AMAG Pharmaceuticals posted sales of $153.74 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 14.6%. The business is expected to issue its next earnings results on Thursday, November 1st.
According to Zacks, analysts expect that AMAG Pharmaceuticals will report full year sales of $538.46 million for the current fiscal year, with estimates ranging from $516.59 million to $554.63 million. For the next financial year, analysts anticipate that the company will report sales of $422.63 million per share, with estimates ranging from $376.79 million to $476.11 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for AMAG Pharmaceuticals.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.54). The firm had revenue of $146.25 million for the quarter, compared to analysts’ expectations of $156.26 million. AMAG Pharmaceuticals had a negative net margin of 36.87% and a negative return on equity of 2.77%. The company’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.40) EPS.
Several analysts have issued reports on the stock. ValuEngine raised shares of AMAG Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, June 6th. BidaskClub raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 14th. Leerink Swann assumed coverage on shares of AMAG Pharmaceuticals in a research note on Monday, May 21st. They issued a “market perform” rating and a $24.65 price objective for the company. B. Riley raised shares of AMAG Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $23.00 to $30.00 in a research note on Friday, June 15th. Finally, Janney Montgomery Scott downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $20.00 price target for the company. in a research note on Friday, June 15th. Seven investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $22.85.
Shares of AMAG Pharmaceuticals stock traded down $0.55 during trading on Monday, reaching $23.80. 462,900 shares of the stock traded hands, compared to its average volume of 882,545. The firm has a market cap of $841.14 million, a price-to-earnings ratio of -4.28 and a beta of 0.48. AMAG Pharmaceuticals has a 52-week low of $11.93 and a 52-week high of $26.10. The company has a quick ratio of 1.95, a current ratio of 2.06 and a debt-to-equity ratio of 0.99.
In related news, CEO William K. Heiden sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the chief executive officer now owns 328,015 shares of the company’s stock, valued at $8,200,375. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.00% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Legal & General Group Plc raised its stake in AMAG Pharmaceuticals by 6.0% in the second quarter. Legal & General Group Plc now owns 67,795 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after buying an additional 3,827 shares in the last quarter. Alps Advisors Inc. grew its holdings in AMAG Pharmaceuticals by 9.0% in the second quarter. Alps Advisors Inc. now owns 49,816 shares of the specialty pharmaceutical company’s stock worth $971,000 after purchasing an additional 4,096 shares during the last quarter. New York State Teachers Retirement System grew its holdings in AMAG Pharmaceuticals by 11.9% in the first quarter. New York State Teachers Retirement System now owns 38,625 shares of the specialty pharmaceutical company’s stock worth $778,000 after purchasing an additional 4,100 shares during the last quarter. Northern Trust Corp grew its holdings in AMAG Pharmaceuticals by 1.0% in the first quarter. Northern Trust Corp now owns 458,445 shares of the specialty pharmaceutical company’s stock worth $9,237,000 after purchasing an additional 4,468 shares during the last quarter. Finally, BNP Paribas Arbitrage SA grew its holdings in AMAG Pharmaceuticals by 8.5% in the second quarter. BNP Paribas Arbitrage SA now owns 88,180 shares of the specialty pharmaceutical company’s stock worth $1,720,000 after purchasing an additional 6,883 shares during the last quarter.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Featured Story: What is a closed-end mutual fund (CEF)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.